TABLE 3

Differentially expressed pathways in DKD glomeruli

Canonical pathwaysPRatioMolecules
Integrin signaling4.77E–062.06E–01FYN, RAC2, ITGA8, MYLK3, ITGB8, PIK3R4, RHOH, ITGB7, PTEN, PTK2, MYLK, ARF6, ITGAV, AKT3, VCL, ACTN1, ITGB5, PARVA, TSPAN5, PAK2, RRAS, ACTB, CRKL, RAC1, TSPAN2, BCAR3, ITGA3, ITGB3, ROCK1, ITGB2, WIPF1, ITGAM, ARF5, RHOQ, TSPAN1, PLCG2, CAPN1, CAPN2, PIK3CD, ACTN4, TSPAN6, NEDD9, and FNBP1
Complement system1.96E–053.71E–01CD59, C3, CD55, C1QA, CD46, C1QB, CFB, C4A/C4B, C7, CFH, C3AR1, CR1, and C2
Leukocyte extravasation signaling8.13E–051.91E–01RAC2, MMP7, NCF1C, CLDN7, MAPK13, RAPGEF4, PIK3R4, RHOH, PTK2, CLDN4, CYBB, MMP11, VCL, PRKD1, ACTN1, TIMP2, TIMP3, MMP28, ACTB, CRKL, RAC1, RDX, RAPGEF3, NCF4, DLC1, ROCK1, BTK, ITGB2, WIPF1, CLDN5, ITGAM, JAM3, ICAM3, PLCG2, CD44, PIK3CD, ACTN4, and CTNND1
Hepatic fibrosis/hepatic stellate cell activation4.08E–042.04E–01CCR5, CTGF, FN1, LEPR, IL1RL1, CXCR3, CCL5, FAS, VEGFA, COL1A2, TGFBR2, IGF1, HGF, IL1RAP, TIMP2, PDGFRB, SMAD2, VEGFB, FLT1, BAMBI, FGFR2, FGF1, MYL9, COL1A1, KDR, IGFBP3, IL10RA, TGFA, MYH9, and CCR7
Macropinocytosis signaling1.21E–032.24E–01MRC1/MRC1L1, RRAS, RAC1, ITGB8, PIK3R4, CSF1R, ITGB7, ITGB3, ITGB2, ARF6, ABI1, PLCG2, HGF, PIK3CD, ACTN4, PRKD1, and ITGB5
VDR/RXR activation1.32E–032.35E–01WT1, IGFBP6, SERPINB1, CYP24A1, SPP1, IL1RL1, KLK6, CCL5, GTF2B, GADD45A, CEBPA, NCOA1, IGFBP3, VDR, IGFBP1, SEMA3B, CDKN1B, CST6, and PRKD1
Glioma invasiveness signaling2.46E–032.33E–01TIMP3, F2R, RRAS, PIK3R4, RHOH, ITGB3, PTK2, RHOQ, ITGAV, CD44, PIK3CD, ITGB5, FNBP1, and TIMP2
ILK signaling4.53E–031.61E–01FN1, BMP2, ITGB8, PIK3R4, RHOH, PPP1R14B, ITGB7, PTEN, VEGFA, PTK2, TGFB1I1, PPAP2B, AKT3, ITGB5, ACTN1, MUC1, PARVA, VEGFB, ACTB, FERMT2, VIM, ITGB3, MYL9, ITGB2, RHOQ, PPP2R2B, MYH9, LEF1, PIK3CD, ACTN4, and FNBP1
Germ cell-sertoli cell junction signaling6.67E–031.68E–01RAC2, LIMK2, IQGAP1, PIK3R4, RHOH, TUBB2B, PTK2, TGFBR2, AGGF1, PPAP2B, MTMR2, ACTN1, PAK2, TJP1, RRAS, ACTB, TUBB2A, RAC1, TUBA4A, ITGA3, RHOQ, TUBB6, PIK3CD, ACTN4, TUBA3C/TUBA3D, FNBP1, CTNND1, and PVRL2
Virus entry via endocytic pathways8.56E–031.8E–01FYN, RAC2, RRAS, ACTB, CD55, RAC1, ITGB8, ITGA3, PIK3R4, ITGB7, ITGB3, ITGB2, PLCG2, PIK3CD, CXADR, PRKD1, ITGB5, and DNM2
RhoA signaling1.04E–021.68E–01ARHGEF12, PFN1, ACTB, SEPT7, MYLK3, RDX, CDC42EP3, LIMK2, CDC42EP2, DLC1, MYLK, MYL9, PTK2, ROCK1, LPAR1, IGF1, BAIAP2, SEPT2, and CDC42EP4
Inhibition of angiogenesis by TSP11.13E–022.31E–01VEGFA, TGFBR2, FYN, CD47, SDC2, KDR, CD36, AKT3, and MAPK13
Cdc42 signaling1.20E–021.26E–01PAK2, EXOC1, HLA-DMB, LIMK2, MAPK13, CDC42EP2, IQGAP1, ITGA3, CD3D, APC, HLA-DPA1, HLA-DQB1, MYL9, MYLK, WIPF1, IQGAP2, HLA-DQB2, FNBP1 L, BAIAP2, FCER1G, PARD3, and CLIP1
PTEN signaling1.23E–021.63E–01RAC2, RRAS, TGFBR3, FLT1, RAC1, FGFR2, ITGA3, INPP5D, PTEN, TGFBR2, PTK2, CSNK2A2, GHR, BMPR1A, KDR, AKT3, PIK3CD, CDKN1B, MAGI2, and PDGFRB
VEGF signaling1.45E–021.72E–01EIF2S2, VEGFB, RRAS, ACTB, FLT1, PIK3R4, VEGFA, PTK2, ROCK1, PLCG2, KDR, AKT3, PIK3CD, VCL, ACTN4, SFN, and ACTN1
Actin cytoskeleton signaling1.47E–021.39E–01RAC2, PFN1, FN1, F2R, MYLK3, LIMK2, PIK3R4, IQGAP1, MYLK, PTK2, IQGAP2, BAIAP2, DIAPH2, VCL, ACTN1, TIAM1, ARHGEF12, PAK2, RRAS, FGF9, ACTB, CRKL, RAC1, RDX, ITGA3, APC, FGF1, MYL9, ROCK1, CYFIP1, MYH9, PIK3CD, and ACTN4
Role of tissue factor in cancer1.51E–021.75E–01FYN, CTGF, RRAS, RAC1, HBEGF, LIMK2, MAPK13, PIK3R4, ITGA3, F3, EIF4E, ITGB3, PTEN, VEGFA, LCK, ITGAV, AKT3, PIK3CD, RPS6KA1, and ITGB5
Semaphorin signaling in neurons1.76E–022.12E–01PTK2, ROCK1, FYN, ARHGEF12, PAK2, RHOQ, DPYSL3, RAC1, LIMK2, RHOH, and FNBP1
Clathrin-mediated endocytosis signaling1.82E–021.52E–01SH3BP4, RAB4A, EPS15, F2R, SH3GLB1, ITGB8, PIK3R4, ITGB7, VEGFA, ARF6, CD2AP, IGF1, LDLRAP1, DNM2, ITGB5, VEGFB, ACTB, FGF9, RAC1, TSG101, FGF1, ITGB3, ITGB2, CSNK2A2, PIK3CD, and MYO1E
Caveolar-mediated endocytosis signaling1.88E–021.67E–01FYN, ACTB, ITGA8, CD55, CD48, ITGB8, ITGA3, ITGB7, ITGB3, ITGB2, ITGAM, ITGAV, ITGB5, and DNM2
Lipid antigen presentation by CD12.39E–022.17E–01CALR, ARF6, FCER1G, CD1C, and CD1D
Natural killer cell signaling2.58E–021.64E–01FYN, RAC2, PAK2, LAIR1, TYROBP, RRAS, RAC1, PIK3R4, INPP5D, CD300A, LCK, SH2D1A, SYK, PLCG2, FCER1G, AKT3, PIK3CD, and PRKD1
FcγRIIB signaling in B lymphocytes3.83E–021.53E–01BLNK, BTK, RRAS, PLCG2, SYK, PIK3CD, FCGR2B, PIK3R4, and INPP5D
Systemic lupus erythematosus signaling4.11E–021.2E–01CREM, RRAS, IGKC, NFATC1, PIK3R4, FCGR2B, CD3D, FCGR1A, INPP5D, IL33, CD28, LCK, PLCG2, TLR7, FCER1G, C7, IGHM, AKT3, PIK3CD, and FCGR1B
Tight-junction signaling4.36E–021.4E–01TIAM1, TJP1, ACTB, RAC1, CLDN7, PTEN, TGFBR2, MYL9, MYLK, MPDZ, PRKAR2B, CLDN5, CLDN4, MPP5, JAM3, PPP2R2B, CEBPA, AKT3, MYH9, VCL, SPTAN1, MAGI2, and PVRL2
Primary immunodeficiency signaling4.41E–021.43E–01IL7R, BLNK, BTK, LCK, IGKC, IGHM, IGHA1, CD8A, and CD3D
  • The results were obtained from Ingenuity Pathway analysis. P value was determined using Fisher exact test, and the ratio was calculated by dividing the number of molecules present in our study by the total molecules in the pathway. The molecules listed are those differentially regulated in our data.